Clinical trial · Observational
Recurrence and Bleeding in Colorectal Cancer Patients With Cancer-associated Venous Thrombembolism
NCT06440044CI-TRIAL-00078795completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with colorectal cancer (CRC) have a higher risk of both venous thromboembolism (VTE) and major bleeding (MB). Patients with CRC are underrepresented in the major trials examining treatment of cancer-associated VTE with anticoagulant.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bleeding | — | UNRESOLVED | — |
| Colo-rectal Cancer | — | UNRESOLVED | — |
| Thrombosis, Venous | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with adverse anticoagulant outcomes
- description
- Patients with adverse anticoagulant outcomes in the study period. Adverse anticoagulant outcomes include venous thromboembolism recurrence, major bleeding, and clinical relevant non major bleeding.
- interventionNames
- Other: Data collection
- label
- Patients without any adverse anticoagulant outcomes
- description
- Patients without any adverse anticoagulant outcomes in the study period.
- interventionNames
- Other: Data collection
Primary outcomes (3)
- measure
- recurrent VTE including deep vein thrombosis (DVT) and pulmonary embolism (PE)
- timeFrame
- From the date of index VTE to VTE recurrence, assessed up to 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment. 2. CRC patients with VTE treated with an anticoagulant (rivaroxaban or LMWH) for at least six months. Exclusion Criteria: 1\. Participation in this study required active anticoagulant treatment. Apart from this, there were no specific exclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.